Literature DB >> 376551

Deficient serum bactericidal activity against Escherichia coli in patients with cirrhosis of the liver.

J Fierer, F Finley.   

Abstract

The serum bactericidal activity (SBA) of cirrhotic patients was compared with that of normal individuals using the release of (51)Cr from radiolabeled Escherichia coli as the assay method. 80% (22/27) of patients were found to have deficient SBA against at least one of three smooth, serum-sensitive test strains of E. coli. Cirrhotic patients were found to have normal levels of serum lysozyme. Although some patients were mildly hypocomplementemic, this abnormality did not correlate with the presence of a bactericidal defect. Bactericidal antibody in normal and cirrhotics' sera was limited to the immunoglobulin (Ig)M class. Purified IgM from patients with deficient SBA against E. coli 0111 had lower concentrations of bactericidal antibody for that E. coli than did IgM from normal sera; the calculated bactericidal activity of total serum IgM was also lower. The bactericidal defect in cirrhotic serum could be completely corrected by either human antiserum to the homologous strain of E. coli or by purified, normal human IgM. However, because higher concentrations of IgM were required to restore normal SBA to a cirrhotic's serum than to agammaglobulinemic serum, there may be an inhibitor of bactericidal antibody in addition to a deficiency of bactericidal IgM antibody to E. coli in the serum of patients with cirrhosis. The bactericidal activity of the alternative complement pathway was also assessed. Sera from cirrhotic patients had no deficit in SBA attributable to the alternative complement pathway. In fact, in some, the activity of the alternative complement pathway was supernormal, compensating in part for the deficit in IgM-mediated SBA.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376551      PMCID: PMC372032          DOI: 10.1172/JCI109391

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Precise standardization of reagents for complement fixation.

Authors:  J F KENT; E H FIFE
Journal:  Am J Trop Med Hyg       Date:  1963-01       Impact factor: 2.345

2.  Spontaneous colon bacillus bacteremia in Laennec's cirrhosis.

Authors:  W A TISDALE
Journal:  Gastroenterology       Date:  1961-01       Impact factor: 22.682

3.  Bactericidal activity of normal serum against bacterial cultures. II. Activity against Eschericha coli strains.

Authors:  L H MUSCHEL
Journal:  Proc Soc Exp Biol Med       Date:  1960-03

4.  [Portocaval septicemia; liver cirrhosis & septicemia caused by colibacillus].

Authors:  J CAROLI; R PLATTEBORSE
Journal:  Sem Hop       Date:  1958-02-18

5.  Effect of concanavalin A on the functional activity of hemolytic antibody.

Authors:  J J Langone; M D Boyle; T Borsos
Journal:  Immunol Commun       Date:  1977

6.  Role of blocking antibody in disseminated gonococcal infection.

Authors:  J A McCutchan; D Katzenstein; D Norquist; G Chikami; A Wunderlich; A I Braude
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

7.  Hepatic kinetics of 99mtechnetium sulfur colloid in cirrhosis.

Authors:  E A George; J B Shields; E C Cabal; R C Schulz; R M Donati
Journal:  J Nucl Med Allied Sci       Date:  1977 Jul-Sep

8.  Protective role of complement in experimental Escherichia coli endocarditis.

Authors:  D T Durack; P B Beeson
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

9.  Trypan blue inhibits complement-mediated phagocytosis by human polymorphonuclear leukocytes.

Authors:  J C Guckian; W D Christensen; D P Fine
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

10.  Plaque formation and isolation of pure lines with poliomyelitis viruses.

Authors:  R DULBECCO; M VOGT
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

View more
  29 in total

Review 1.  Infections.

Authors:  N Rolando; R J Wyke
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 2.  Problems of bacterial infection in patients with liver disease.

Authors:  R J Wyke
Journal:  Gut       Date:  1987-05       Impact factor: 23.059

3.  Risk of group A meningococcal disease: bacterial interference and cross-reactive bacteria among mucosal flora.

Authors:  G A Filice; P S Hayes; G W Counts; J M Griffiss; D W Fraser
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

4.  Citrate in oral rehydration therapy.

Authors: 
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

Review 5.  Gut microbiome and liver disease.

Authors:  Naga S Betrapally; Patrick M Gillevet; Jasmohan S Bajaj
Journal:  Transl Res       Date:  2016-07-15       Impact factor: 7.012

Review 6.  Infectious complications of liver disease.

Authors:  P D King
Journal:  J Gen Intern Med       Date:  1993-06       Impact factor: 5.128

7.  Liver cirrhosis as a real risk factor for necrotising fasciitis: a three-year population-based follow-up study.

Authors:  Tsung-Hsing Hung; Chen-Chi Tsai; Chih-Chun Tsai; Chih-Wei Tseng; Yu-Hsi Hsieh
Journal:  Singapore Med J       Date:  2014-07       Impact factor: 1.858

8.  Monocyte function in cirrhosis.

Authors:  G Holdstock; B Leslie; S Hill; A Tanner; R Wright
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

9.  Differential complement activation and susceptibility to human serum bactericidal action by Vibrio species.

Authors:  M L Tamplin; S Specter; G E Rodrick; H Friedman
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  Functions of granulocytes and monocytes in primary biliary and alcoholic cirrhosis.

Authors:  A Blussé van Oud; A R Janssens; P C Leijh; R van Furth
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.